Enhanced Risk Stratification in Stage I Melanoma Patients Using DecisionDx-Melanoma Overview Company: Castle Biosciences, Inc. Indication: Stage I Cutaneous Melanoma (CM) Drug/test: DecisionDx-Melanoma Test Trial Phase: Not Applicable NCT ID: Not Available Background Castle Biosciences, Inc. announced on February 26, 2024, a significant enhancement in risk stratification for Stage I Cutaneous Me..
Akili and Shionogi Declare Success in Phase 3 Clinical Trial for EndeavorRx as ADHD Treatment for Japanese Children Overview Company: Akili, Inc. & Shionogi & Co. Ltd Indication: Pediatric ADHD Drug: SDT-001 (localized version of AKL-T01 / EndeavorRx) Trial Phase: Phase 3 NCT ID: N/A Akili, Inc., in collaboration with Shionogi & Co. Ltd, announced the successful completion of a Phase 3 clinical ..
CG Oncology Initiates PIVOT-006 Phase 3 Trial for Cretostimogene Targeting Intermediate-risk NMIBC Overview Company: CG Oncology, Inc. Indication: Intermediate-risk Non-Muscle Invasive Bladder Cancer (NMIBC) Drug: Cretostimogene Trial Phase: Phase 3 NCT ID: NCT06111235 Trial Details On February 27, 2024, CG Oncology announced the commencement of their Phase 3 PIVOT-006 clinical trial. This pivot..
Tonix Pharmaceuticals Reveals Promising Pharmacokinetics of Cyclobenzaprine for Fibromyalgia in Japan and China Company: Tonix Pharmaceuticals, Inc. Indication: Fibromyalgia Drug: Tonmya™ (TNX-102 SL, cyclobenzaprine HCl sublingual tablets) Trial Phase: Phase 3 NCT ID: N/A Overview Tonix Pharmaceuticals, Inc., a pioneering biopharmaceutical company, disclosed favorable outcomes from its pharmaco..
Hoth Therapeutics Advances Preclinical Development of HT-KIT With Altasciences Collaboration for Mast Cell-Derived Cancer Treatment Overview Company: Hoth Therapeutics, Inc. Indication: Mast Cell-Derived Cancers Drug: HT-KIT Trial Phase: Preclinical (N/A for IND-enabling studies) Nct ID: Not applicable Development Update Hoth Therapeutics, Inc., a patient-focused biopharmaceutical company, has a..
Advancement in Acute Myeloid Leukemia Treatment: Kura Oncology Initiates Phase 1 KOMET-008 Trial with Ziftomenib in Combination Therapies Overview Kura Oncology, Inc., a company leading the way in precision medicine for cancer, has begun a promising new clinical trial for Acute Myeloid Leukemia (AML) treatment. Clinical Trial Details Company: Kura Oncology, Inc. Indication: Acute Myeloid Leukemi..
electroCore, Inc. has recently announced an exclusive distribution agreement with Reliefband Technologies, LLC. This agreement allows electroCore to distribute Reliefband's ReletexTM device within the Department of Veterans Affairs and other eligible entities. The Reletex device is a non-invasive neuromodulation device that has been cleared by the FDA for the treatment of nausea and vomiting. As..
